How Much Revenue Could Pfizer’s Oral COVID-19 Pill Fetch?

How Much Revenue Could Pfizer’s Oral COVID-19 Pill Fetch?
Paxlovid, a Pfizer COVID-19 pill, is seen manufactured in Ascoli, Italy, in this undated photo obtained by Reuters on Nov. 16, 2021. Pfizer/Handout via Reuters
Benzinga
Updated:
Pfizer Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.

Pfizer Analysts

SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.
BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.

Broad Label, Increased Supply to Give Pfizer Dominant Market Position

Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for its molnupiravir more than a month ahead of Pfizer, Porges said in a note.